The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood by Osaro, Erhabor & Charles, Adias Teddy
© 2011 Osaro and Charles, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Blood Medicine 2011:2 7–21
Journal of Blood Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
7
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/JBM.S17194
The challenges of meeting the blood transfusion 
requirements in Sub-Saharan Africa: the need for 
the development of alternatives to allogenic blood
erhabor Osaro1
Adias Teddy Charles2
1Department of Medical Laboratory 
Sciences, College of Health Sciences, 
Niger Delta University, Amassoma 
Bayelsa State, Nigeria; 2Department  
of Medical Laboratory Science,  
Rivers State University of Science and 
Technology, Port Harcourt, Nigeria
Correspondence: erhabor Osaro 
Department of Blood Sciences, Royal 
Bolton Hospital, Bolton, UK 
Tel +44 7932363217 
email n_osaro@yahoo.com
Abstract: As a resource, allogenic blood has never been more in demand than it is today. 
  Escalating elective surgery, shortages arising from a fall in supply, a lack of national blood 
transfusion services, policies, appropriate infrastructure, trained personnel, and financial 
resources to support the running of a voluntary nonremunerated donor transfusion service, and 
old and emerging threats of transfusion-transmitted infection, have all conspired to ensure that 
allogenic blood remains very much a vital but limited asset to healthcare delivery particularly 
in Sub-Saharan Africa. This is further aggravated by the predominance of family replacement 
and commercially remunerated blood donors, rather than regular benevolent, nonremunerated 
donors who give blood out of altruism. The demand for blood transfusion is high in Sub-Saharan 
Africa because of the high prevalence of anemia especially due to malaria and pregnancy-related 
complications. All stakeholders in blood transfusion have a significant challenge to apply the 
best available evidenced-based medical practices to the world-class management of this   precious 
product in a bid to using blood more appropriately. Physicians in Sub-Saharan Africa must 
always keep in mind that the first and foremost strategy to avoid transfusion of allogenic blood 
is their thorough understanding of the pathophysiologic mechanisms involved in anemia and 
coagulopathy, and their thoughtful adherence to the evidenced-based good practices used in 
the developed world in a bid to potentially reduce the likelihood of allogenic blood transfusion 
in many patient groups. There is an urgent need to develop innovative ways to recruit and 
retain voluntary low-risk blood donors. Concerns about adverse effects of allogenic blood 
transfusion should prompt a review of transfusion practices and justify the need to search for 
transfusion alternatives to decrease or avoid the use of allogenic blood. These strategies should 
include the correction of anemia using pharmacological measures (use of antifibrinolytics to 
prevent bleeding and the use of erythropoietin and oral and intravenous iron to treat anemia) 
use of nonpharmacologic measures (preoperative autologous blood transfusion, perioperative 
red blood cell   salvage and normothermia to reduce blood loss in surgical patients). All these 
strategies will help optimize the use of the limited blood stocks.
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Introduction
Blood transfusions worldwide currently face interesting challenges. Transfusion-
transmissible infections, such as HIV, hepatits B virus (HBV), hepatitis C virus 
(HCV), syphilis, and malaria have provoked a greatly heightened emphasis on safety 
with inescapable implications for the complexity and cost of providing a transfusion 
service. One of the biggest challenges to blood safety particularly in Sub-Saharan 
Africa is accessing safe and adequate quantities of blood and blood products.1 
  Communities in Africa face several enduring challenges: chronic blood shortages, high   Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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prevalence of transfusion-transmissible infections (TTIs), 
lack of national blood transfusion services, recruitment 
and retention of   voluntary nonremunerated donors, family 
replacement and commercial blood donation, and inadequate 
use of pharmacologic and nonpharmacologic alternatives 
to allogenic blood. Addressing these challenges should 
be a central priority for most blood transfusion services, 
particularly in Sub-Saharan African countries, to ensure the 
uninterrupted supply of safe blood and blood products. The 
aim of this review is to highlight the challenges associated 
with meeting the blood transfusion requirements in Sub-
Saharan Africa.
Challenges of recruitment of 
voluntary nonremunerated donors
Globally, approximately 80 million units of blood are donated 
each year.2 Of this total, 2 million units are donated in 
Sub-Saharan Africa, where the need for blood transfusions 
is great because of maternal morbidity, malnutrition, and 
a heavy burden of infectious diseases such as malaria. 
  Several factors have led to the World Health Assembly 
  resolutions WHA28.723 and WHA58.134 urging member 
states to develop national blood transfusion services based 
on voluntary nonremunerated blood donation: the chronic 
shortage of safe blood and blood products particularly in 
  low- and medium-income countries; the need to prevent 
  transmission of HIV and other blood-borne pathogens 
through unsafe blood and blood-product transfusions by 
  collecting blood only from donors at the lowest risk of 
carrying such infectious agents; and the recognition that 
voluntary, nonremunerated blood donation is the cornerstone 
of a safe and adequate national blood supply that meets the 
transfusion requirements of all patients. The collection of 
blood only from voluntary, nonremunerated blood donors 
is an important measure for ensuring the safety, quality, 
availability, and accessibility of blood transfusion. Innovative 
ways to recruit and retain voluntary donors in Sub-Saharan 
Africa include: celebration of the gift of blood donation; 
recognition of voluntary blood donors; increasing public 
awareness of voluntary nonremunerated blood donation; 
educating the public on the importance of regular, voluntary, 
nonremunerated blood donation; educating the public on 
the benefits of voluntary nonremunerated blood donation 
to recipients; promoting healthy living (nutrition, exercise, 
lifestyle); and provision of noncash incentives to encourage 
people to donate blood. Blood safety remains an issue of 
major concern in transfusion practice in most countries in 
Sub-Saharan Africa where national blood transfusion services 
and policies, appropriate infrastructure, trained personnel, 
and financial resources are inadequate to support the running 
of a voluntary, nonremunerated donor transfusion service. 
This is further aggravated by the predominance of family 
replacement and commercially remunerated blood donors, 
rather than regular, benevolent, nonremunerated donors who 
give blood through altruism.
Despite recommendations that all blood donors should 
be voluntary and nonremunerated, replacement donors are 
common throughout Sub-Saharan Africa.5 The primary 
steps of setting up a national blood transfusion program 
include: the enactment of a national policy for the blood 
transfusion service with time-bound programs; a centrally 
coordinated, structured, and organized blood transfusion 
service under a defined authority for a country/state; a blood 
transfusion service based on an organized voluntary blood 
donor   program; screening blood for TTIs appropriate to 
the region; appropriate and evidence-based use of available 
blood and blood products; and employment and retention of 
qualified personnel to lead and manage the blood transfusion 
service.6 In many countries in Sub-Saharan Africa, most of 
these steps are in place, and sometimes there are none. There 
is lack of political will and open-mindedness to innovative 
ways to improve supply and safety of blood from voluntary 
donors. The effect of this failure in the stewardship of blood 
and blood products is that the incidence of TTIs is gener-
ally high. Blood transfusions are a substantial source of 
HIV in Sub-Saharan Africa especially among women with 
pregnancy-related complications and children with malaria 
and malnutrition-associated anemia.7 The maintenance of 
a high-quality blood supply depends on blood volunteers, 
government funding of blood services, adequate supervision 
of commercial blood supplies, and professionals who   collect, 
test, and supply safe blood.8 In a bid to making blood transfu-
sion safe in African Countries, the US President’s Emergency 
Plan for AIDS Relief (PEPFAR) in 2004   provided technical 
and financial support to strengthen national blood transfusion 
services in 14 countries in Africa and the Caribbean with high 
prevalence of HIV infection. PEPFAR has supported efforts 
to improve blood supply adequacy and safety by providing 
policy guidance, strengthening laboratory infrastructure, and 
enhancing blood donor recruitment and retention practices. 
Assessment carried out on data collected by national blood 
transfusion services in these 14 countries during 2003 to 
2007 found that national policies had been established in 
12 of the 14 countries; the number of whole blood units 
collected had increased in all 14 countries, the percentage 
of collections from voluntary, nonremunerated donors had   Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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increased and the percentage of collected blood units reactive 
for HIV had decreased in 13 of the 14 countries.9 In most 
  developed countries, safe, low-risk voluntary donated 
blood and blood products is   supplied by the national blood 
  transfusion service.10,11 Evidence of good practice from these 
countries is a clear indication that with political will and 
open mindedness to evidence-based   practices, it is possible 
to run a safe national blood transfusion service involving 
a voluntary, low-risk, nonremunerated blood program in 
most countries in Sub-Saharan Africa.12 Some countries in 
Sub-Saharan Africa are already implementing best practices 
in blood transfusion. Burkina Faso is a continental West 
African country of approximately 16 million people whose 
transfusion needs are covered by 66,210 blood units collected 
mostly in 4 regional transfusion centers, which are part of 
a national network, and also from hospital-based smaller 
blood centers. The first group of blood centers relies almost 
exclusively on volunteer, nonremunerated, blood donors, only 
approximately 32.7% of whom are repeat donors. Challenges 
being encountered include the low overall blood supply which 
worsens during the secondary school recesses since young 
students constitute the majority of volunteer donors.13,14 The 
Kumasi Teaching Hospital Blood Centre in Ghana and a local 
FM radio station recently developed a partnership calling 3 
times a year for donation at the radio station where music, 
entertainment, and token gifts are available. A total of 3801 
donors attended the program and 92% of the potential FM 
donors were eligible to donate. The use of a culturally and 
socially adapted environment to make the gift of blood a 
pleasurable and festive experience can generate a new pool of 
blood donors and spontaneously repeating donations.15 Blood 
transfusion in Djibouti is organized with reference to relevant 
French regulation. The system is   basically a family donor 
system. Spontaneous donations mainly from police and army 
personnel account for only 20% of the 2500 units collected 
each year.16 Several countries in Africa can learn from good 
practice in other sister countries that are already implement-
ing a national blood transfusion program based on voluntary 
nonremunerated donors.17 Voluntary nonremunerated blood 
donors are considered safer than family replacement donors 
and, in particular, commercial or professional donors. 
Establishing a panel of regular, voluntary, nonremunerated 
blood donors is therefore the most effective way of ensuring 
adequate ongoing supplies of safe blood. Education is an 
essential part of a donor recruitment strategy. A donor educa-
tion motivation and recruitment campaign has 3 basic goals: 
to promote changes in the public’s knowledge, attitudes, and 
beliefs so that they understand why blood donation is a vital, 
life-saving service to the community; to promote changes in 
people’s behavior so that they become willing to donate blood 
on a regular, voluntary basis, without payment; and to ensure 
that potential donors understand the importance of safe blood 
so that they do not donate blood if they are in poor health or 
at risk of transmitting TTIs. Educational material such as 
leaflets, posters, films, and videos play an important part in 
donor recruitment campaigns.18
Developing countries face considerable obstacles to 
ensuring a safe blood supply and safe blood transfusions. 
Becasue developing countries tend to have inadequate 
available blood supplies, they depend on family blood 
donors.19 A family replacement donor is one who gives 
blood when it is required by a member of the donor’s fam-
ily or   community. One disadvantage of this method of 
blood donation is that patients or their relatives are under 
intense strain when the patient is admitted to   hospital. Being 
expected to provide replacement donors puts additional 
responsibility and stress on relatives, and there is undue 
pressure on family members to give blood, even when they 
know that donating blood may affect their own health or 
that they may be potentially at risk of transmitting TTIs.20,21 
A country’s transfusion needs cannot easily be met by relying 
solely on family replacement donations.22 The World Health 
Assembly recommended that reliance on replacement dona-
tions should be phased out due to their association with an 
increased risk of TTIs.14,23 Meeting the transfusion needs of 
recipients is challenging because donated blood may not nec-
essarily be replaced in type or quantity.24 This leaves relatives 
who cannot find suitable donors with no other option than 
to seek commercialy remunerated, high-risk blood donors. 
Blood donated by certain relatives, particularly spouses of 
women of child-bearing age, can put their wives/partners 
potentially at risk of producing antibodies to clinically sig-
nificant antigens that the husband and the developing fetus 
may have but which the wife lacks. There are increasing 
concerns about the sustainability of centralized voluntary 
donor systems and their compatibility with the suboptimal 
level of healthcare facilities existing in many Sub-Saharan 
African countries, yet burdening patients’ families with 
the responsibility of finding replacement blood donors will 
exacerbate poverty and reduce the safety of the blood sup-
ply.20 There has been a huge debate as to whether the Western 
model of a centralized blood service with 100% voluntary 
nonremunerated blood donors as advocated by the World 
Health Organization (WHO) fits the African setting.25,26
Blood safety remains an issue of major concern in 
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Africa. This is further aggravated by the predominance of 
  commercially remunerated blood donors, rather than regular, 
benevolent, nonremunerated donors who give blood as a 
result of altruism. Reports in most countries in Sub-Saharan 
Africa have indicated a high prevalence of TTIs among 
commercially remunerated blood donors.27,28 Commercially 
remunerated donors often come from the poorest sectors 
of the economy, may be poor in health, are more likely to 
give blood more often than recommended, and are also at a 
higher risk of being undernourished and having a TTI from 
high-risk behaviors such as maintenance of multiple sex 
partners, intravenous drug abuse, and unprotected sexual 
intercourse.29–32
Challenge of transfusion-
transmissible infections
Syphilis
Over the years, much controversy has arisen over the 
need for syphilis testing of blood donors.33 Although the 
American Association of Blood Banks initially dropped its 
recommendation that donors be tested for syphilis in 1978, 
the US Food and Drug administration (FDA) has maintained 
this requirement. This FDA decision was reinforced by the 
HIV epidemic. It is now recommended in most countries 
that surrogate testing including syphilis should be done 
to prevent those at risk from donating blood.24 Studies to 
investigate the risk of transfusion-transmissible syphilis 
among blood donors in Ghana have indicated an antibody 
seroprevalence rate of 13.5% for Treponema palladium.34 
Similarly, a study of 252 first-time donors in Cameroon 
indicated a 9.1% prevalence rate for syphilis and a signifi-
cantly increased risk in HIV-positive donors.20 Screening of 
TTIs among blood donors can be a cost-effective approach 
to monitor the prevalence, distribution, and trends of the 
infections among blood donors. However, cost of TTI 
testing is a major challenge to the provision of safe blood 
and blood products in Sub-Saharan Africa. A recent report 
has indicated that treponemics, nontreponemics, immuno-
chromatographics, or nucleic acid testing is affordable and 
can significantly contribute to blood transfusion safety, as 
in most resource-poor countries.20 A cross-sectional study 
in Nigeria, a country at the elementary stages of setting up 
of a national blood transfusion service, to detect antibodies 
to T. pallidum using Clinotech syphilis test strips (Clino-
tech Diagnostics, Canada) involving a total of 1410 appar-
ently healthy prospective blood donors yielded an overall 
seroprevalence of 1.1%.35 A study in Mali to determine the 
risk of transfusion-transmissible syphilis infection among 
Malian blood donors showed a seroprevalence rate of 0.3% 
and a higher risk among donations from first-time and 
replacement donors compared to voluntary and repeated 
donors.36
Malaria
Malaria is a serious public health problem in Africa. 
In 2008, there were more than 247 million new cases and 
approximately 1 million deaths.37 In spite of this fact, there 
is no consensus for measures to prevent post-transfusion 
malaria in endemic areas. Malaria remains a rare but serious 
complication of transfusion because of the asymptomatic 
  persistence of parasites in some donors. In nonendemic 
countries, the predominant strategy of deferral or cellular 
component discard from ‘high-risk’ donors is effective in 
minimizing the incidence, but wasteful. In endemic   countries 
where recipients are commonly immunized, transfusion 
strategies focus on chemoprophylaxis for the donor and 
recipient or ensuring that blood collected in highly endemic 
regions is not transfused to patients from areas of low 
endemicity.38 The provision of a secure and safe blood supply 
has been a major concern in Sub-Saharan Africa with high 
malaria endemicity. A study involving 3001 blood donors 
recruited in 7 blood transfusion centers in Senegal during 
2 periods, dry season (June–July 2003) and rainy season 
(October–November 2003), has shown an anti-Plasmodium 
antibodies prevalence of 65.3% and parasite-specific lactate 
dehydrogenase antigen prevalence of 0.53%. Plasmodium 
represents the third most common risk in Senegalese donors 
of blood-transmitted infectious agents after HBV and 
syphilis, and more common than HCV and HIV .39 Similarly 
a study using giemsa-stained blood films from 1018 consecu-
tively recruited blood donors in Nigeria has shown an overall 
prevalence rate of (10.2%). Infection rate was significantly 
higher among commercially remunerated donors com-
pared to family replacement donors and voluntary donor.40 
Recently, 391 consecutively recruited potential blood donors 
in a malaria-endemic area of south-western Nigeria were 
investigated for malarial parasitemia using three methods: 
microscopy (all samples), OptiMAL (TCS Biosciences 
Ltd) (315 samples) and/or the Clinotech Malaria Cassette 
(142 samples). OptiMAL detects parasite-specific lactate 
dehydrogenase whereas the Clinotech test detects the surface 
proteins of merozoites and sporozoites. Microscopy revealed 
parasitemias in (20.2%) of the potential donors, the levels of 
parasitemia varying from 34 to 6289 asexual parasites/µL 
(mean = 445/µL). The prevalence of malarial parasitemia, 
as detected by microscopy, was significantly higher during Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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the rainy season than in the dry season and there was no sig-
nificant association between level of parasitemia and fever.41 
Cheap and inexpensive examination of giemsa-stained blood 
films can be a readily available minimal alternative to other 
more expensive malaria screening methods, particularly in 
low-income countries in Sub-Saharan Africa.42–44 A study 
has suggested that antimalarial prophylaxis be added to local 
programs against the vectors of the disease in transfusion 
recipients, particularly children and pregnant women, in 
malaria endemic countries.45 The risk of introducing an 
unsafe and potentially dangerous transfusion-transmitted 
malaria is often lethal, particularly in Plasmodium falci-
parum infection. The administration of antimalarials to 
transfusion recipients may help to   prevent transmission. 
Nonetheless, no matter what strategy is adopted, it is likely 
that cases of transfusion-transmitted malaria may still occur, 
so malaria must always be considered in any patient with a 
febrile illness post-transfusion.46
HCv
Screening donated blood for HCV is important for HCV 
  prevention and is routinely practiced in most countries. 
The risk of HCV transmission through the transfusion of 
unscreened blood has led to the systematic screening of 
blood donors in many settings in Sub-Saharan Africa. HCV 
is recognized as the primary cause worldwide of transfusion-
associated non-A–non-B viral hepatitis47 and is endemic 
in West Africa.48 The prevalence and cost-effectiveness of 
testing HCV among 2592 consecutive blood donors was 
investigated in Uganda. Overall, 4.1% of specimens were 
HCV enzyme immunoassay (EIA) reactive. Specimens 
repeatedly reactive on EIA were tested with a recombi-
nant immunoblot assay (RIBA). Of the 4.1% EIA-reactive 
specimens, 0.6% were RIBA positive and 1.8% were RIBA 
indeterminate.49 Similarly a study carried out on 1565 blood 
donors recruited at the National Blood Transfusion Centre 
(CNTS) in Senegal, Dakar using two different techniques 
for the testing of HCV (ELISA technique and immunoblot 
RIBA), indicated an HCV ELISA positive test in 1.4% and 
a RIBA positive test in 0.25% of donors. One of the HCV-
positive donors was co-infected with HBV (HCV/HBV).50 
The presence of anti-HCV antibodies was determined in the 
serum of 300 blood donors in Port Harcourt, Nigeria using a 
second-generation rapid screening test, the HEP C SPOT™ 
HCV assay. Initially reactive results were confirmed by 
repeat testing with UBI HCV EIA 4.0 enzyme immunoassay. 
Fifteen of the 300 donors were positive for HCV , giving a 
prevalence rate of 5.0%. HCV prevalence was significantly 
higher among commercially remunerated donors.51 A study 
to investigate the risk of transfusion-transmissible HCV 
infection among 808 blood donors in Ghana indicated 8.4% 
prevalence after initial testing and the seroprevalence of HCV 
infection was confirmed to be 0.9% after supplementary 
testing.52 A   retrospective study involving 4731 blood donors 
in Kaduna, Nigeria to determine the seroprevalence of HCV 
among blood donors indicated 1.8% prevalence.53 A total of 
4633 regular blood donors screened over a 3-year period at 
the Department of Haematology and Blood Transfusion at the 
Ahmadu Bello University Teaching Hospital, Zaria, Nigeria 
has shown a 5.2% HCV prevalence.54 Similarly a study under-
taken to establish the sero-epidemology of HCV antibodies 
among 1500 blood donors in Port Harcourt, Nigeria detected 
HCV antibodies in 0.5% donors. Commercially remunerated 
donors had a higher prevalence of anti-HCV antibodies 
(0.8%) than family replacement and voluntary donors.55 
Similarly a HCV prevalence study involving 260 healthy 
volunteer male donors in Benin City, Nigeria indicated a very 
high prevalence of 12.3%.56 In a study investigating the risk 
of transfusion-transmissible HCV infection in Sub-Saharan 
Africa, the median overall risk of becoming infected with 
HCV from a blood transfusion was 2.5 infections per 1000 
units.57 In 2005, the South African National Blood Service 
introduced individual-donation (ID) nucleic acid test (NAT) 
screening for HCV RNA. The HCV ID-NAT window phase 
yield rate in 732,250 blood donations was 1:732,200. The 
residual transmission risk of HCV ID-NAT window phase 
donations was estimated at 1:21,000,000.58 Despite the known 
facts that proper blood donor recruitment and selection and 
adequate laboratory screening for infectious markers dimin-
ish the risk of TTIs and that HCV is among the greatest threats 
to blood safety in Sub-Saharan Africa, it is sad to note that 
some blood transfusion centers in Sub-Saharan Africa may 
not be screening blood donors for HCV .59
Hiv
Blood transfusion continues to be an important route of 
  transmission of HIV particularly in developing   countries 
among young children and pregnant women after transfusion 
for malaria-associated anemia and pregnancy-related 
complications.60 A study undertaken to determine the 
seroprevalence of HIV infection among 1500 blood 
donors living in the Niger Delta area of Nigeria showed a 
  prevalence of 1.0%. The highest prevalence occurred among 
  commercially remunerated donors.61 Similarly a study of 
33,682 and 1259 blood donors screened in 2 tertiary hospitals 
in Nigeria indicated overall HIV seroprevalence of 7.66% Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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and 0.71%, respectively.62,63 Two studies to   investigate 
the risk of transfusion-transmissible HIV infection among 
Malian blood donors indicated prevalences of 2.6%36 and 
4.5%, respectively.64 Undetectable HIV infections in blood 
banks pose a serious threat to public health.65 In Kenya, 
blood donations from high school students are preferred over 
adult samples due to the lower HIV infection prevalence 
within this population. However a study carried out using 
Stimmunology, an in vitro lymphocyte stimulation technique, 
has revealed a significant number of early, preseroconversion 
HIV carriers both among adult and teenage Kenyan 
populations.66,67 A mathematical model constructed to 
quantify transfusion risks across 45 Sub-Saharan African 
countries used 3   components: the risk of a contaminated 
unit entering the blood supply, the risk that the unit will be 
given to a susceptible patient, and the risk that receipt of the 
unit will lead to infection in the recipient. Variables included 
prevalence of infection in donors, extent of blood testing, test 
sensitivity, and susceptibility of recipients. Data from the 
WHO African Region and a systematic review of the litera-
ture were used to parameterize the model. Data suggest that 
the median overall risk of becoming infected with HIV from 
a blood transfusion in Sub-Saharan Africa was 1 infection 
per 1000 units.57 The majority of donor blood in Zimbabwe 
comes from school-based donors. Zimbabwe has one of the 
highest HIV prevalences in the world and the age at which 
the infection is acquired is decreasing. This is a serious threat 
to the safety of blood supply. The prevalence of HIV has 
been low among the youth, the majority of whom are still 
going to school and are between the ages of 16 and 19 years. 
However, due to the changing socio-economic environment, 
sexual behavioral patterns have also changed. It is now nec-
essary to evaluate these changes in order to guarantee safe 
blood transfusion. A study to determine the prevalence of 
HIV among adolescent donors in Zimbabwe between 2002 
and 2003 revealed that the prevalence of HIV in 2002 and 
2003 was 0.48% and 0.38%, respectively.   Prevalence was 
higher among first-time and female donors.68 A study to 
estimate the prevalence of transfusion-transmissible HIV 
infection in 2 groups of blood donors at Douala city over 
the period 1995 to 2004 indicated that the prevalence of 
HIV ranged from 2.2% to 8.12% at the Douala   University 
and 7.89% at the blood bank of Laquintinie Hospital.69 
  Remunerated and   family replacement donors are at more 
risk of being HIV positive.70 Areas with high HIV-incidence 
rates compared with those in the developed world may 
benefit from additional testing in blood banks and may 
show more favorable cost-effectiveness ratios. A study in 
Korle Bu Teaching Hospital in Ghana, where only HIV 
antibody screening was employed for blood donor screening, 
  evaluated the cost-effectiveness of adding p24 antigen, 
mini-pool nucleic acid   amplification   testing (MP-NAT), or 
ID-NAT to the HIV-antibody screening. The residual risk 
of HIV transmission was derived from blood donations 
to the blood bank and the remaining life expectancies of 
patients receiving blood transfusion were estimated using 
the WHO life   expectancies. Cost-effectiveness ratios for 
adding the tests to HIV-antibody screening were determined 
using a decision tree model and a Markov model for HIV . 
The prevalence of HIV was estimated at 1.51% in 18,714 
donations during 2004. The incremental cost per disability-
adjusted life-year (DALY) averted was US$1237 for p24 
antigen, US$3142 for MP-NAT and US$7695 compared 
with the next least expensive strategy. HIV-antibody screen-
ing itself was cost-saving compared with no screening at all, 
gaining US$73.85 and averting 0.86 DALY per transfused 
patient. Up to a willingness-to-pay of US$2736 per DALY 
averted, HIV-antibody screening without additional testing 
was the most cost-effective strategy. Over a willingness-
to-pay of US$11,828 per DALY averted, ID-NAT was 
significantly more cost-effective than the other strategies.71 
A 5-year descriptive and prospective study in Cameroon 
was conducted in which information on donor blood and 
recipients was obtained by direct patient observation and 
by examining patient notes in the various services of 
the hospital and records from the blood bank. Of 40,134 
donations, 35,318 (88%) were from relatives or friends of 
recipients. Only 80% of all donated blood was considered 
safe for distribution. An average of about 20% of donated 
blood was rejected each year for positive HIV or hepatitis 
B antigen results.72
HBv
HBV is the most common cause of serious liver   infection in 
the world. Worldwide, it is estimated that more than 2 billion 
people have been infected by HBV and 350   million people have 
chronic infection. HBV is highly contagious and transmission 
of HBV occurs through percutaneous or   permucosal routes, 
infective blood or body fluids   introduced at birth, sexual 
  contact, or contaminated needles.   Transfusion-transmitted 
HBV infection is   increasingly becoming a major mode of 
transmission of HBV in   high-prevalence areas in Sub-  Saharan 
Africa. Rate of positive donations per blood unit collected 
among Malian blood donors was 13.9%. Hepatitis B surface 
antigen (HBsAg) -positive donations were significantly 
higher among donations from replacement donors than those Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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from volunteer donors.37 A cross-sectional study undertaken 
to determine the seroprevalence of HBsAg among 1410 
apparently healthy prospective blood donors in Nigeria 
observed an overall seroprevalence of 18.6%.73 A study to 
estimate the prevalence of transfusion-transmissible HBV in 
2 groups of blood donors at Douala city over the period 1995 
to 2004 indicated that the seroprevalence for HBV ranged 
from 6.10% to 16% for donors at Douala University, while 
at the blood bank of Laquintinie Hospital the prevalence 
was 6.91%.69 Between January and August 1999, a total of 
7277 blood donors at various health centers in Kinshasa, 
Democratic Republic of the Congo were screened for HBsAg 
using the ELISA technique. Findings showed an incidence 
of 9.2%.74 A cross-sectional study conducted to assess the 
prevalence of HBV, and its co-infection among 11,592 
blood donors at the National Blood Transfusion Centre in 
Bamako, Mali, indicated a prevalence of 14.9%. The HIV/
HBV co-infection rate was only 1.13% in this population.66 
A prospective cross-sectional study was conducted in the 
regional center of blood transfusion in Bouaké. Among 1231 
new blood donors tested, HBsAg prevalence was 12.5%.75 
Studies to investigate the risk of transmission of HBV infec-
tion in blood donors in Jos, Benin, and Port Harcourt (all in 
Nigeria) indicated prevalences of 15.1%, 5.8%, and 4.98%, 
respectively.76–78 Similarly, in a study to estimate the residual 
risks of HBV infection in Conakry calculated from the 
incidence cases number, rate incidence for 100,000 person-
years was estimated and multiplied by the period of mute 
serological window for HBV (56 days) in order to estimate 
the residual risk. Residual risk was 1/121 blood donations for 
HBV .79 The seroprevalence rate of HBsAg among 349 blood 
donors in Nouakchott, Mauritania has shown an HBsAg 
prevalence of 20.3%.80 Screening for AgHBs carried out in 
9006 volunteer blood donors at the National Blood Bank in 
the Republic of Djibouti from 1998 to 2000 demonstrated 
HBsAg prevalence of 10.4%.81
Challenges of red cell 
alloimmunization
Red blood cell (RBC) alloimmunization results from genetic 
disparity of RBC antigens between donor and recipients. 
Alloimmunization is significant especially when it involves 
a clinically significant alloantibody that causes hemolytic 
  transfusion reactions and hemolytic disease of the newborn. 
It is very important that alloantibodies be correctly, and 
some of them routinely, typed in blood donors as well as in 
patients.82 The development of RBC isoimmunization with 
alloantibodies and autoantibodies complicates transfusion 
therapy particularly in multiply-transfused patients.83 
A report84 observed that the overall incidence of RBC alloim-
munization in transfused patients was 3.4% (18/531), with 
anti-c being the most common specificity (38.8%), followed 
by anti-E (22.2%), anti-M (11.1%), anti-Le(a) (11.1%), 
anti-D (5.6%), anti-Jk(a) (5.6%), and anti-Le(b) (5.6%). 
Alloimmunization to red cell antigens is still a current 
problem in many settings in Sub-Saharan Africa. Antenatal 
screening of 3000 patients who were grouped and screened in 
Zimbabwe indicated an overall antibody incidence of 1.7%. 
Antibodies identified from patients were: anti-D 13.3%, 
anti-E 6.7%, anti-Js(b) 3.2%, anti-Le(a) 23.3%, and anti-
Le(b) 20%.85 Alloantibody testing of transfusion recipients 
to ensure that they receive RBCs negative to the alloantibody 
they may have developed is often lacking; there is an absence 
of universal access to prophylactic immunoglobulin D for 
the prevention of Rh isoimmunization in Rh-negative86 
women coupled with the absence of cost-effective means 
of estimating fetomaternal hemorrhage in many settings in 
Sub-Saharan Africa. These factors all complicate transfu-
sion practice in this region. It is obvious that the additional 
testing of blood donors for clinically significant RBC anti-
gens as well as alloantibody screening of all recipients for 
which RBC transfusion is indicated should be implemented 
as a routine to prevent as far as possible the incidence 
of alloimmunization.87,88 It would also be cost-effective, 
bearing in mind the fact that laborious and expensive labo-
ratory testing is necessary to provide compatible blood for 
alloimmunized patients. Extended blood typing should be 
implemented for some categories of polytransfused patients 
as well. This strategy is another step forward to improving 
the safety of blood transfusion in Africa.89
Challenges of suboptimal  
use of nonpharmacologic  
and pharmacologic alternatives  
to allogenic blood
Autologous blood transfusion
The three main techniques for autologous blood transfusion 
(ABT) are predeposit autologous donation, acute normov-
olemic hemodilution, and perioperative cell salvage. ABT 
is extremely safe, and crossmatching is not required; isoim-
munization to foreign protein is excluded and the fear of 
TTIs can be ignored.90 Some of the complications associated 
with allogenic blood are immunological, and are thought 
to be responsible for the increase in tumor recurrence after 
surgical resection,91 increased postoperative infection rates,92 Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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increased progression of HIV infection,93 and multi-organ 
failure.94 These sequelae can be reduced by the use of 
autologous blood. Experience in many Sub-Saharan African 
countries has shown that ABT can help prevent the use of 
allogenic blood.90
Perioperative RBC salvage entails the collection and 
reinfusion of blood lost during or after surgery. Shed blood is 
aspirated from the operative field into a specially designed 
centrifuge. Citrate or heparin anticoagulant is added, and 
the contents are filtered to remove clots and debris. Devices 
used can vary from simple, inexpensive, sterile bottles 
filled with anticoagulant to expensive, sophisticated, high-
speed cell washing devices. A retrospective audit of the 
medical records of all Jehovah’s Witnesses who underwent 
  neurosurgical   procedures from January 1 2000 to December 
31 2006 in Tema, Ghana showed that it is possible to perform 
certain types of neurosurgical procedures in Jehovah’s 
  Witnesses without using allogenic blood and increasing the 
mortality and morbidity rate.95 Hemorrhage from ruptured 
ectopic pregnancy is a major cause of maternal death 
in Africa. The experience in St. John of God Hospital, 
  Tanguiéta, Benin Republic in salvaging intraperitoneal 
blood with a perforated metallic conical funnel in 212 
patients has shown that the incidence of allogenic blood use 
is reduced. The postoperative   hemoglobin level increased to 
84.7 ± 10.5 g/L 6 days postoperatively from a preoperative 
level of 70.6 ± 18.7 g/L after the transfusion of 681 ± 389 mL 
(n = 212) of salvaged blood.96 A review97 showed that 
intraoperative blood salvage (IBS) and ABT is a simple, 
effective, and safe method of blood replacement and that its 
use should be of primary   consideration in the   management 
of ruptured ectopic pregnancy. A prospective study was 
conducted at the Saint-Jean-de-Dieu Hospital in Afghan 
(Togo) among 75 patients who received   indication of ABT 
and accepted the protocol. The most frequent interventions 
were hysterectomies (21%), bone surgery (16%), and pros-
tatectomies (11%). Fifty-six percent of patients received 
transfusion in gynecological surgery, 79% in orthopedics, 
and 88% in urology. Only 1 patient received an additional 
homologous unit of blood. ABT seems a   feasible, effective, 
and secure method that could be implemented in Sub-Saharan 
African countries. It may be a solution to the problems of 
shortage of blood products and transfusion safety. However 
training and motivation are necessary for its successful 
implementation.98,99 IBS is used extensively after blunt 
abdominal trauma, but when blood is contaminated by enteric 
contents its use has been considered contraindicated. A ran-
domized, controlled trial conducted in an inner city trauma 
unit in Johannesburg, Republic of South Africa in patients 
with penetrating torso injury requiring a laparotomy showed 
that IBS significantly reduced allogeneic blood use with no 
discernable effect on postoperative infection or mortality 
rates.100 Experience with autologous blood use at the plastic 
surgery unit of the National Orthopaedic Hospital, Enugu, 
Nigeria and Kenyatta National Hospital, Nairobi has shown 
that autologous blood is cheaper, safe, not associated with 
greater untoward reactions than homologous blood, and 
that it should be considered in elective surgical cases.101,102 
In Saint-Louis’ Regional Hospital, Senegal transfusion risks 
and blood shortage led to the introduction of delayed ABT 
despite a great number of difficulties. Results have shown 
that ABT can be implemented in an African setting and that 
it can help optimize the use of the limited allogenic blood 
stock.103 A study involving intraoperative ABT performed in 
48 of 90 women with ectopic pregnancy in Tanzania between 
1990 and 1995 indicated that the procedure appeared safe 
and useful.104
Predeposit autologous donation entails repeated preopera-
tive phlebotomy 4 to 5 weeks before surgery, during which 
time 4 or 5 units of in-date blood can be collected with ease. 
This technique reduces exposure to allogeneic blood. It 
avoids many of the risks of transfusion, especially immuni-
zation to red cell/platelets/human leukocyte antigens and the 
transmission of infection. Acute normovolemic hemodilution 
(‘hemodilution’) is a form of ABT performed preoperatively 
in the operating theater or anesthetic area. It is usually 
restricted to patients in whom substantial blood loss (.1 L or 
20% of blood volume) is predicted. Whole blood (1.0–1.5 L) is 
removed, and simultaneously intravascular volume is replaced 
with crystalloid or colloid, or both, to maintain blood volume. 
The anticoagulated blood is then reinfused during or shortly 
after surgical blood loss has stopped in reverse order of col-
lection. A study was carried out in Bugando Medical Centre, 
Mwanza, Tanzania105 to identify the best method of ABT to 
be applied in an East African hospital among 109 consecutive 
patients for whom major blood loss was expected. Seventeen 
patients donated 1 unit of blood 3 days preoperatively and 92 
underwent acute isovolemic hemodilution prior to induction 
of anesthesia. For the hemodiluted patients a 2:1 ratio of 
sterile pryogen-free saline to collected blood was used. One 
of the 16 patients from whom 2 units were withdrawn by 
hemodilution experienced hypovolemia, which was rapidly 
restored by additional transfusion of colloid. Of the patients 
who donated blood preoperatively only 23.5% were autotrans-
fused compared to 98.9% of the hemodiluted patients. Of the 
latter 23.9% (22) had an intraoperative blood loss exceeding Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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15% of their total blood volume and 7.6% (7) lost more than 
25%. Only 1 received homologous blood in addition. The 
  investigators concluded that in hospitals with limited blood 
bank   facilities and regular cancellation of surgery, the use 
of acute isovolemic hemodilution is recommended. A 3:1 
ratio of saline to blood is now advised when 1 unit is with-
drawn and a part replacement with crystalloid when 2 units 
are collected.106 Similarly a prospective case-control study 
involving 40 cases to investigate the feasibility of differed 
ABT at Point “G” National Hospital in Bamako, Mali showed 
that the procedure was well accepted by all the patients. No 
  clinical or biological effects have been reported by the patients 
themselves. The authors recommend the use of ABT by other 
hospital units and the development of regulations governing 
its implementation.107
Normothermia
Another important, less emphasized, measure to reduce blood 
loss through preservation of hemostasis is the maintenance 
of normothermia both during and after the operation. Many 
studies have emphasized the major role of hypothermia in 
the onset of bleeding during surgical procedures. Valeri 
and associates108 observed the effects of skin temperature in 
33 patients undergoing cardio pulmonary bypass operation. 
Local hypothermia produced an increased bleeding time and 
a significant reduction in the thromboxane B2 level at the 
bleeding time site. Local rewarming produced a significant 
increase in the shed blood and thromboxane B2 level. 
Hypothermia can cause a reversible platelet dysfunction 
and rewarming can improve platelet function and reduce 
both bleeding time and blood loss. This hypothesis has been 
confirmed109 in a report that demonstrated the involvement of 
platelet glycoprotein receptor (glycoprotein Ib and granule 
membrane protein 140) alterations in this hemostatic defect. 
Again, rewarming completely reversed the activation defect 
as soon as temperature returned to 37°C. Other studies have 
shown an important prolongation of prothrombin time and 
activated partial thromboplastin time, which was inversely 
correlated with temperature.110
Use of erythropoietin
The availability and use of hemopoietic growth factors 
on a large scale for in vivo and in vitro management of 
anemia has opened a new era in transfusion medicine. 
  Erythropoietin (EPO) was the first hemopoietic growth 
factor identified. Many anemic patients being managed with 
EPO alone or with some combined strategy of EPO plus 
red cell replacement have shown that the RBC transfusion 
requirement is substantially reduced.111–113 Anemia is fre-
quently diagnosed in patients with cancer. A systematic 
literature review (1996–2003) to produce evidence-based 
guidelines on the use of EPO in anemic patients with cancer 
shows that RBC transfusion requirements are significantly 
reduced with EPO protein therapy in patients with chemo-
therapy-induced anemia or when used to prevent cancer 
anemia. Level I and III evidence indicates that patients 
with chemotherapy-induced anemia or anemia of chronic 
disease initially classified as nonresponders to standard 
doses proceed to respond to treatment following a dose 
increase.114 Similarly a report on treatment with epoetin 
alpha as a single weekly dose significantly increased hemo-
globin levels in patients with cancer who were undergoing 
radiotherapy. The response was greater in patients treated 
with radiotherapy alone than in those receiving combined 
therapy. The duration of EPO treatment was shorter in the 
group treated with radiotherapy alone than in the combined 
treatment group.115 Experience with preoperative single 
weekly dose of 150 µg/kg of EPO in Ghanaian patients 
showed that it is effective in raising preoperative hemo-
globin.116 A report assessing the effectiveness and safety of 
early initiation of EPO (initiated before 8 days after birth) 
in reducing RBC transfusions in preterm and/or low-birth-
weight infants indicated that early administration of EPO 
reduces the likelihood of  transfusion of one or more units 
of RBCs, the volume of RBCs transfused, and the number 
of donors and transfusions to which the infant is exposed.117 
Cost and availability of EPO is a major challenge in Sub-
Saharan Africa. Poor use of EPO is more likely in countries 
that have lower annual per capita health care expenditures, 
lower proportions of privately funded health care, and a 
national health service.118 Financial considerations and 
a hemoglobin level ,10 g/dL appear to influence EPO 
use in the United States, whereas financial considera-
tions alone determine EPO use elsewhere, particularly in   
Sub-Saharan Africa.
Use of oral and intravenous iron
Most pre-school children and pregnant women in developing 
countries and at least 30% to 40% in developed countries have 
been estimated to be iron deficient.119 The high prevalence 
in Africa is due to multiple and complex factors related to 
several underlying mechanisms, which include inadequate 
diet, poor iron absorption in the alimentary canal, increased 
iron requirements owing to low birth weight, growth, 
pregnancy, or lactation, and chronic blood loss resulting from 
parasitic infections including hookworm. Intravenous iron Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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treatment is a readily available option for treating women 
with postnatal anemia.120
Several studies evaluating the therapeutic effectiveness, 
safety, and cost of intravenous iron and oral iron therapy 
over RBC transfusion have found iron therapy more cost 
effective particularly because crossmatching is not required, 
risk of isoimmunization to foreign protein is absent, and 
the fear of TTIs can be ignored. In a study of repeated RBC 
transfusion in anemic gynecologic cancer patients   receiving 
  platinum-based chemotherapy comparing intravenous and 
oral iron showed that intravenous iron is an alternative 
  treatment in these patients and reduces the incidence of 
RBC transfusion without serious adverse events.121 Although 
the cost of intravenous iron sucrose therapy may seem high 
  compared to oral, a lack of adherence to therapy and side 
effects including gastrointestinal irritation during oral iron 
therapy were not experienced during intravenous therapy.122–124 
However, consensus exists that concurrent blood transfusion 
and iron supplementation should be avoided.
Antifibrinolytics
Concerns about the safety of transfused blood have led 
to the development of a range of interventions to mini-
mize blood loss during major surgery. Although the use 
of antifibrinolytics may not seem cost-effective in most 
African settings,   studies have shown that antifibrinolytics 
(aprotinin, tranexamic acid, epsilon-aminocaproic acid) 
reduce blood loss in   orthopedic surgery,126 scoliosis,127 and 
coronary bypass surgery.128 Aprotinin and tranexamic acid 
reduced significantly the proportion of patients requiring 
allogeneic erythrocyte transfusion according to a transfu-
sion protocol.129 Recently, questions have been raised on 
the comparative performance of the drugs and the safety 
of the most popular agent, aprotinin. Antifibrinolytic drugs 
provide worthwhile reductions in blood loss and the need 
for allogeneic RBC transfusion.130 Postpartum hemorrhage 
is a leading cause of maternal death particularly in Sub-
Saharan Africa. It also contributes to maternal morbidity as 
women may require a hysterectomy to control bleeding, or 
may require a blood transfusion, which can transmit viral 
infections.   Antifibrinolytics have been proposed as a treat-
ment for postpartum hemorrhage.131 The administration of 
tranexamic acid was associated with a reduction in blood 
loss of 92 mL (95% confidence interval 76 to 109). A review 
of the use of aprotinin as prophylaxis to prevent bleeding 
indicates that it reduces the need for RBC transfusion, and 
the need for reoperation due to bleeding, without serious 
adverse effects.132
Factor VIIa
Octaplex® (Octapharma Limited UK), a prothrombin   complex 
concentrate (PCC), is available as a powder and   solvent 
for solution for injection containing human prothrombin 
  complex. It nominally contains human   factor II, VII, IX 
X, and Protein S and C. It is indicated for the treatment 
of bleeding and perioperative prophylaxis of bleeding in 
acquired deficiency of the prothrombin complex coagulation 
factors, such as deficiency caused by treatment with vitamin K 
antagonists, or in case of overdose of vitamin K antagonists, 
when rapid correction of the deficiency is required. There 
are an increasing number of anecdotal reports and trials of 
recombinant activated factor VII (rFVIIa) for bleeding during 
surgery. A report by McCall and colleagues in Canada133 
on the audit of FVIIa use for the management of bleeding 
  following complex cardiac surgery showed that use of rFVIIa 
in cardiac surgery may be effective, but definitive clinical 
trials are needed to clarify its role in clinical practice and 
safety. Major blood loss can often be life-threatening and is 
most commonly encountered in the settings of surgery and 
trauma. Patients receiving anticoagulant therapy are also at 
increased risk of bleeding. A report from Plymouth, United 
Kingdom134 investigated the use of a PCC (Beriplex® P/N, 
CSL Behring, Marburg, Germany) to treat severe bleeding 
in a variety of settings: cardiac surgery, warfarin therapy, 
and other surgery. The results of this study highlight a 
potential role for PCC in controlling bleeding in patients 
undergoing cardiac surgery and other surgical procedures and 
in   reducing, and sometimes abolishing, the need for allogenic 
blood in surgical and nonsurgical patients. However, some 
of these may remain unavailable to patients, particularly in 
Sub-Saharan Africa, because of financial constraints on the 
healthcare system. Nonetheless, physicians in Africa must 
always keep in mind that the first and foremost strategy 
to avoid transfusion of allogenic blood is their thorough 
understanding of the pathophysiologic mechanisms involved 
in anemia and coagulopathy, and their thoughtful adherence 
to evidence-based good practices in the developed world 
can potentially reduce the likelihood of allogenic blood 
transfusion in many patient groups.
Use of restrictive RBC transfusion 
practices and transfusion triggers
Most clinical practice guidelines recommend restrictive 
RBC transfusion practices, with the goal of minimizing 
exposure to allogeneic blood. The current evidence sup-
ports the use of restrictive transfusion triggers in patients 
who are free of serious cardiac disease and suggests that Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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critically ill patients tolerate anemia well and that blood 
transfusions may increase the risk of adverse outcomes.135,136 
However, data from randomized controlled trials suggest 
that overall morbidity (including cardiac) and mortality, and 
hemodynamic, pulmonary, and oxygen transport variables 
do not differ between restrictive (transfusion threshold 
between 70 and 80 g/L) and liberal transfusion strategies, and 
that a restrictive transfusion strategy is not associated with 
increased adverse outcomes. In fact, a restrictive strategy may 
be associated with decreased adverse outcomes in younger 
and less sick critical care patients. The majority of existing 
guidelines conclude that transfusion is rarely indicated when 
the hemoglobin concentration is greater than 100 g/L and 
is almost always indicated when it falls below a threshold 
of 60 g/L in healthy, stable patients or more in older, sicker 
patients.137 A retrospective audit over a 1-year period in 2 
Dutch hospitals showed that a proportion of RBC transfu-
sions seem unnecessary and advocated that evaluation of the 
indications for and the appropriateness of RBC transfusions 
in the postpartum patient is vital.138
Use of artificial oxygen carriers
The expected cost explosion in transfusion medicine 
resulting from an increasing imbalance between donors 
and   recipients, and treatment of transfusion-associated 
  complications, has increased the socio-economic significance 
of the development of safe and effective synthetic oxygen 
carriers as an alternative to the transfusion of allogeneic 
RBCs.139 However, a recent review of artificial oxygen 
  carriers indicated that despite decades of preclinical and 
clinical research on them, the results were disappointing. In 
Russia, a perflourocarbon (Perftoran) is available locally and 
in South Africa the only approved hemoglobin-based oxygen 
carrier (Hemopure) is little used. Other products, just prior 
to filing for FDA approval, did not achieve convincing study 
results and research and production was stopped. Adverse 
reactions such as hypotension and pulmonary complication 
have significantly affected their widespread use despite their 
potential role in the reduction of preoperative allogeneic 
blood transfusion. In the light of these challenges, it seems 
that the global clinical establishment of artificial oxygen 
carriers should not be expected in the near future.140
Fluid resuscitation after massive hemorrhage in major 
surgery and trauma may result in extensive hemodilution and 
coagulopathy.141 After extensive hemodilution, fibrin clots 
are more prone to fibrinolysis because major antifibrinolytic 
proteins are decreased. Cryoprecipitates are considered 
the mainstay hemostatic therapies in such   situations. 
  Purified factor concentrates (fibrinogen) of plasma origin 
and from recombinant synthesis are increasingly used in 
the management of bleeding associated with dilutional 
coagulopathy to rapidly restore targeted factors.142 Purified 
fibrinogen concentrate has been used extensively in the 
management of major obstetric hemorrhage.143
Cultural and awareness-related 
challenges associated with blood 
donors and their distribution  
in Sub-Saharan Africa
Some controversy exists about whether there are insufficient 
voluntary donations. Countries in Sub-Saharan Africa need 
to find ways of maintaining sufficient blood supply from 
  voluntary nonremunerated donors and improving blood 
safety from the available replacement donors. In brief, the 
reason why replacement donors remain the main source of 
blood in Sub-Saharan Africa is that it costs less to procure and 
fits well with the African culture of extended family support. 
The mentality of altruism through the voluntary donation of 
blood is not as accepted in Sub-Saharan Africa as in most 
developed countries. Only an insignificant number of eligible 
donors actually donate blood in most Sub-Saharan African 
countries. There is no feeling of optimistic altruism in most 
African settings. Several issues influence donor motivation 
and perceptions in Sub-Saharan Africa. Several prejudices 
and misconceptions affect the principle of altruism in Sub-
Saharan Africa, including cultural differences and lack of 
information. Studies conducted in Burkina Faso, South 
Africa, Togo and Nigeria indicate that blood donors have 
unfounded fears: fear of knowing one’s HIV serologic status, 
fear of being infected with diseases, and the erroneous belief 
that donating blood can decrease one’s libido, cause weight 
loss, cause high blood pressure, or even lead to death.144,145 
More effort is required in the drive for education, motivation, 
and recruitment of regular donors. Most studies in Africa 
report a male dominance in blood donation programs (61% in 
Togo),145 (71.2% in Burkina Faso),146 and (90% in Ghana).147 
In a recent survey in Central, Western, and Eastern franco-
phone African regions, all 7 countries surveyed reported less 
than 30% females in their donor population.148 Reports from 
anglophone East and Southern African countries have also 
shown a male dominance in blood donation programs.149 The 
reason for this male gender predisposition to blood donation 
is based on the erroneous belief that men are healthier than 
women,150 coupled with the general belief that women make 
monthly blood donations to nature through their menstrual 
cycle. Other factors such as pregnancy and breastfeed-Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18
Osaro and Charles
ing further restrict many women from donating blood in   
Sub-Saharan Africa. Interestingly this pattern seems to differ 
significantly from what is found in some developed countries 
of Europe. In 2003 female blood donors represented 40% of 
the blood donor population in Austria, 49.7% in France, 50% 
in Norway, and 55% in Great Britain.151
Conclusion
We advocate that commercially remunerated donation of 
blood be discouraged. Political will and open-mindedness 
to innovative ways to improve supply and safety of blood 
are essential to promote more evidence-based approaches to 
blood transfusion practice in Sub-Saharan Africa. We have 
a significant challenge to reduce unnecessary demand 
through world-class management of this precious product 
and the application of the best available evidenced-based 
medical practices. Strategies that reduce the use of allogenic 
blood, such as the correction of perioperative anemia, 
pharmacological and nonpharmacologic measures to reduce 
blood loss, preoperative autologous blood donation, and and 
perioperative red blood cell salvage, should be implemented 
to enable the optimal use of our limited blood supply in 
patients in whom these approaches are contraindicated.
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